Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Clear all

Conditions: Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: Latanoprost, Arm 2, Latanoprost SR insert; Drug
Lead sponsor: Daniel Moore; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Ocular Surface Disease, Glaucoma, Open-Angle
Interventions: iStent or iStent inject implantation with concomitant cataract surgery; Device
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 22 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost SR, LUMIGAN; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more

Conditions: Glaucoma, Glaucoma, Open Angle
Interventions: SOLX Gold Shunt; Device
Lead sponsor: SOLX, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: Birmingham, Alabama • Springdale, Arkansas • Irvine, California + 8 more

Conditions: Open Angle Glaucoma
Interventions: Travoprost; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 13
States / cities: Hemet, California • Petaluma, California • Fort Collins, Colorado + 10 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: DE-104 medium concentration, DE-104 high concentration, Placebo, 0.005% latanoprost; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Artesia, California • Pasadena, California • San Francisco, California + 3 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Travoprost, Latanoprost; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: High Dose Device, Low Dose Device, Placebo Device; Drug · Device
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Artesia, California • Louisville, Kentucky • Baltimore, Maryland + 1 more

Conditions: Glaucoma
Interventions: Surgery, Selective Laser Trabeculoplasty; Procedure
Lead sponsor: University of Kentucky; Other
Eligibility: 40 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Glaucoma, Open-Angle
Interventions: Images of eye at 2 eye pressures; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions: QLS-111-FDC, Latanoprost (0.005%); Combination Product · Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Largo, Florida

Conditions: Primary Open Angle Glaucoma, Open Angle Glaucoma
Interventions: Minimally Invasive Micro Sclerostomy Device; Device
Lead sponsor: Sanoculis Ltd; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: laser trabeculoplasty; Other
Lead sponsor: Santa Clara Valley Health & Hospital System; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Jose, California

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 1,540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2022
U.S. locations: 3
States / cities: Birmingham, Alabama • La Jolla, California • New York, New York

Conditions: Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts
Interventions: anterior segment OCT; Device
Lead sponsor: Duke University; Other
Eligibility: 40 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glaucoma, Ocular Hypertension (OH)
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Springdale, Arkansas • Denver, Colorado • Danbury, Connecticut + 8 more

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: Nanodropper, Regular dropper; Device
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Primary Open-angle Glaucoma (POAG) Patient
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 40 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Ocular Hypertension, Open-Angle Glaucoma
Interventions: Latanoprost Punctal Plug Delivery System, Xalatan; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions: SHP639 (n=60), Placebo Comparator (n=24); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Open Angle Glaucoma
Interventions: Suprachoroidal Dissection Instrument (SDI); Device
Lead sponsor: iScience Interventional Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Safety Study of Latanoprost Slow Release Insert

Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

SOLX Gold Shunt for Refractory Glaucoma

Study of Exchange of Travoprost Intraocular Implant

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Safety and Efficacy of a Glaucoma Drug Delivery System

Effects of Selective Laser Trabeculoplasty

Optic Nerve Head Strain as Biomarker for Glaucoma

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Evaluation of Pascal Laser Trabeculoplaty

African Descent and Glaucoma Evaluation Study

Imaging Lens Deposits in Exfoliation Syndrome

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

Surgical Treatment of Refractory Open Angle Glaucoma

Topical Insulin for Glaucoma (TING2)